drugset / Trial / NCT01348009
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
Cisplatin, an intravenously administered platinum agent, in combination with an intravenously administered taxane and capecitabine has been shown to improve time to disease progression and overall survival in previously untreated patients with gastric cancer. This study is being performed to evaluate an orally administered taxane (tesetaxel) in combination with cisplatin and capecitabine in previously untreated patients with gastric cancer.
Timeline
- Start
- 2011-05
- Primary completion
- 2013-10
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesetaxel | Small molecule | 18 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 21 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 24 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 27 mg/m2 | Oral |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Background | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |